Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

What is the Role for TKIs in RCC? Highlights from the 18th Annual Meeting of the SUO

Program Information
What is the Role for TKIs in RCC? Highlights from the 18th Annual Meeting of the SUO
Dr. Vitaly Margulis discusses the role of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma from the Society of Urologic Oncology Conference.

Available credits: 0.75

Time to complete: 45 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Jointly provided by    and 

    Although renal cell carcinoma (RCC) accounts for only 2% to 3% of all adult cancers, for those who present with or progress to advanced RCC, the 5-year survival rate has never been above 10%. Several tyrosine-kinase inhibitors (TKIs), along with many other therapies, now occupy a preferred role in treatment of patients with advanced RCC, but this is a rapidly changing field. The emergence of immunotherapy for patients with RCC is reshaping the landscape of treatment options for both patients with relapse/stage IV surgically unresectable RCC and neoadjuvant therapy. Moreover, advances in the understanding of RCC biomarkers may help to identify which patients may benefit from certain therapies allowing for the possibility of more individualized treatment plans. This interactive activity features an interview with a leading expert in RCC as he discusses the current trends in clinical research in RCC treatment and how these findings are expected to impact not only guideline development but also more individualized patient care. This expert interview was recorded at and discusses some of the latest data featured at the 18th Annual Meeting of the Society of Urologic Oncology in Washington, DC.

  • Goal

    The goal of this activity is to provide oncologists, urologists, nurses, nurse practitioners, and physician assistants, who manage patients with RCC, with updates to the ongoing research in RCC treatment, the ever-changing roles of TKIs in patients with RCC, and the anticipated changes in the national guidelines for this population in 2018.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    • Outline the latest clinical research and potential role of neoadjuvant therapy in patients with RCC.
    • Indicate current and future advanced RCC sequential treatment regimens with TKIs. 
  • Target Audience

    This activity is intended for healthcare professionals (oncologists, urologists, nurses, nurse practitioners, and physician assistants) who care for patients with metastatic RCC. 

  • Participating Faculty

    Course Director
    Vitaly Margulis, MD
    Associate Professor
    Department of Urology
    University of Texas Southwestern Medical Center
    Dallas, Texas

    Release Date: May 15, 2018

    Expiration date: May 15. 2019

    Estimated time to complete activity: 45 minutes.

    Media: Internet 

  • Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


    Physician Continuing Medical Education
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Nursing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is .7 contact hours.

    Designated for 0.3 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

     Name of Faculty or Presenter 

     Reported Financial Relationship

       Vitaly Margulis, MD

     Consultant for: Astellas Pharma US and Pfizer, Inc. 

       Barnett Mennen, MD

     Nothing to Disclose

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The ASiM CE LLC planners and managers have nothing to disclose.

  • Method of Participation and Request for Credit

    There are no fees for participating and receiving CME credit for this activity. During the period May 15. 2018 through May 15, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on after listening to and participating in this enduring material. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warning.

  • Disclaimer


    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    To contact Postgraduate Institute for Medicine, please email

  • Commercial Support

    This activity is supported by an independent educational grant from Pfizer, Inc.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 7/18/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.